Screener Summaries Updates Institutions Sign In More Updates › Other Events › IMMP Other Events · Jun 4, 2026
Immutep Limited announced that it will present positive interim Phase I data for its first-in-class LAG-3 agonist… IMMP IMMUTEP Ltd
Immutep Limited announced that it will present positive interim Phase I data for its first-in-class LAG-3 agonist antibody, IMP761, at the EULAR 2026 conference. No specific financial or clinical figures were provided in the filing.
All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
